- I-Mab (IMAB, Financial) will host a webinar on July 8, 2025, at 2:00 PM EDT to discuss new Phase 1b data for givastomig.
- The discussion will include givastomig's use in combination with nivolumab and chemotherapy for Claudin 18.2-positive metastatic gastric cancers.
- Dr. Samuel J. Klempner from Massachusetts General Hospital will lead the webinar, featuring Phase 1b data from 17 patients.
I-Mab (IMAB), a global biopharmaceutical company, has announced an upcoming virtual investor webinar set for July 8, 2025, at 2:00 PM EDT. This event aims to recap the presentation of new clinical data on their Claudin 18.2 x 4-1BB bispecific antibody, givastomig, initially revealed at the ESMO GI 2025 conference. The original data presentation is scheduled for July 2, 2025, at 16:50 CEST during the ESMO GI Congress.
The webinar will provide insights into the Phase 1b dose escalation study evaluating the efficacy and safety of givastomig combined with nivolumab and chemotherapy in first-line treatment for patients with Claudin 18.2-positive metastatic gastric cancers. The study included data from 17 patients, showcasing promising outcomes as part of the ongoing research.
The event will feature Dr. Samuel J. Klempner, an Associate Professor at Massachusetts General Hospital, as the key opinion leader. He will discuss the significant findings from the combination dose escalation study. A live question-and-answer session will follow the presentation. For those unable to attend, a replay of the webinar will be accessible on I-Mab's website for 90 days.
I-Mab continues to develop givastomig with the potential for expanded use in other solid tumors, aiming to create a new standard for the treatment of Claudin 18.2-positive cancers. This development is part of a partnership endeavor with ABL Bio, emphasizing I-Mab's commitment to advancing precision immuno-oncology.
